2seventy bio, Inc. (NASDAQ:TSVT) Receives Consensus Rating of “Moderate Buy” from Brokerages

2seventy bio, Inc. (NASDAQ:TSVT) has received an average rating of “Moderate Buy” from the nine brokerages that are currently covering the firm, Marketbeat reports. One analyst has rated the stock with a sell recommendation, three have issued a hold recommendation, four have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month target price among brokerages that have covered the stock in the last year is $9.00.

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of 2seventy bio in a research report on Saturday, January 18th.

Hedge Funds Weigh In On 2seventy bio

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Geode Capital Management LLC lifted its stake in shares of 2seventy bio by 1.1% in the 3rd quarter. Geode Capital Management LLC now owns 1,176,244 shares of the company’s stock valued at $5,553,000 after purchasing an additional 13,144 shares during the period. XTX Topco Ltd boosted its position in shares of 2seventy bio by 61.1% during the third quarter. XTX Topco Ltd now owns 24,416 shares of the company’s stock valued at $115,000 after buying an additional 9,257 shares during the last quarter. Wellington Management Group LLP grew its stake in shares of 2seventy bio by 9.0% in the third quarter. Wellington Management Group LLP now owns 262,040 shares of the company’s stock worth $1,237,000 after acquiring an additional 21,673 shares during the period. Western Standard LLC bought a new stake in 2seventy bio in the 3rd quarter worth approximately $1,350,000. Finally, State Street Corp increased its position in 2seventy bio by 1.5% during the third quarter. State Street Corp now owns 1,058,773 shares of the company’s stock valued at $4,997,000 after acquiring an additional 15,638 shares during the last quarter. Institutional investors own 93.90% of the company’s stock.

2seventy bio Stock Performance

NASDAQ TSVT opened at $2.51 on Friday. The company has a market capitalization of $129.49 million, a P/E ratio of -1.35 and a beta of 1.76. The company has a fifty day moving average of $3.17 and a 200-day moving average of $4.12. 2seventy bio has a 52-week low of $2.35 and a 52-week high of $6.40.

2seventy bio Company Profile

2seventy bio, Inc, a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma.